Trial Profile
Chemoprevention in BRCA1 mutation carriers - a proof of concept study
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2020
Price :
$35
*
At a glance
- Drugs Anastrozole (Primary) ; Goserelin (Primary) ; Tamoxifen (Primary)
- Indications Breast cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms CIBRAC
- 05 Sep 2020 Status changed from recruiting to discontinued.
- 09 Sep 2018 Planned End Date changed from 21 Jul 2018 to 21 May 2018.
- 20 Jan 2017 New trial record